Autoinjectors Market

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023

Report Code: MD 6494 Aug, 2018, by marketsandmarkets.com

[133 Pages Report] The overall autoinjectors market is expected to grow from USD 25.84 billion in 2017 to USD 85.31 billion by 2023, at a CAGR of 24.2% from 2018 to 2023. Autoinjectors offer several advantages, such as reduces the chances of needlestick injuries, reduce needle phobia anxiety, maintain consistency regarding dose accuracy, and aid in better efficacy, which, in turn, help in the growth of the market. The autoinjectors market is expanding with the technological advancement and new design development. These autoinjectors are being used in many therapies such as rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.

Autoinjectors Market

Market Dynamics

Drivers

  • Growing prevalence of targeted therapies
  • Rising incidence of anaphylaxis
  • Increasing number of regulatory approvals
  • Availability of generic versions of autoinjectors

Restraints

  • Preference for alternative drug delivery modes

Opportunities

  • Patent expiry of biologics to drive the demand for biosimilars

Challenges

  • Development of autoinjectors for multiple drug viscosities
  • Lack of proper training for using autoinjectors

Use of autoinjectors in the treatment of rheumatoid arthritis drives the global autoinjectors market

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues. It causes joints to swell and can result in pain, stiffness, and progressive loss of function. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia. Thus, the demand for autoinjectors for this therapy segment is fueled by the increasing incidence of RA across the globe. Among the various treatment options available for RA in the market, autoinjectors are the most advanced and convenient mode of tretment currently avialble in the market.

Autoinjectors Market

The following are the major objectives of the study.

  • To describe and forecast the autoinjectors market, in terms of value, by type, therapy, and end users
  • To describe and forecast the autoinjectors market, in terms of value, by region–Asia Pacific (APAC), Europe, North America, and Rest of the World (RoW) along with their respective countries
  • To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To study the complete value chain of autoinjectors
  • To analyze opportunities in the market for stakeholders by identifying the high-growth segments of the autoinjectors ecosystem
  • To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing competitive landscape for market leaders
  • To analyze strategic approaches such as product launches, acquisitions, contracts, agreements, and partnerships in the autoinjectors market

During this research study, major players operating in the autoinjectors market in various regions have been identified, and their offerings, regional presence, and distribution channels have been analyzed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Factiva, along with primary respondents. The entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) pertaining to the market. The figure below shows the breakdown of the primaries on the basis of the company type, designation, and region considered during the research study.

Autoinjectors Market

To know about the assumptions considered for the study, download the pdf brochure

The autoinjectors market comprises a network of players involved in the research and product development; component manufacturing; distribution and sale; and post-sales services. Key players considered in the analysis of the autoinjectors market are Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US). The other prominent players are Merck (US), SHL Group (Taiwan), Ypsomed (Switzerland), AstraZeneca (UK), Becton Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), J&J (US), and Haselmeier (Switzerland).

Major Market Developments

  • In April, 2018, Abbvie and Samsung Bioepis signed a licensing agreement to launch Humira biosimilar in Europe.
  • In August, 2017, Amgen and Humana entered in to collaborative agreement for the development and research of medicines for multiple serious conditions including cardiovascular disease, osteoporosis, neurologic disorders, inflammatory diseases and cancer.
  • In May, 2018, Received EU approval for Repatha autoinjector. Similarly, the company has launched Enbrel auto-touch auto-injector in November, 2017.

Target Audience:

  • Autoinjectors manufacturing companies
  • Original equipment manufacturing companies
  • Suppliers and distributors of autoinjectors
  • Healthcare service providers
  • Teaching hospitals and academic medical centers
  • Health insurance players
  • Government bodies/municipal corporations
  • Regulatory bodies
  • Medical research institutes
  • Business research and consulting service providers
  • Venture capitalists
  • Market research and consulting firms

Report Scope:

The research report categorizes the autoinjectors market into the following segments and subsegments:

By Therapy

  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Diabetes
  • Anaphylaxis
  • Other Therapies (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia)

By Type

  • Disposable Autoinjectors
  • Reusable Autoinjectors

By End User

  • Home Care Settings
  • Hospital & Clinics

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Available customizations

Based on the given market data, MarketsandMarkets offers customizations in the reports as per the client’s specific requirements. The available customization options are as follows:

Geographic Analysis

  • Further country-wise breakdown of the market in APAC based on application

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

The autoinjectors market is expected to reach USD 85.31 billion by 2023 from USD 28.91 billion in 2018, at a CAGR of 24.2% from 2018 to 2023. The market is mainly driven by factors such as growing prevalence of targeted therapies, rising incidence of anaphylaxis, increasing number of regulatory approvals, and availability of generic versions of autoinjectors.

Autoinjectors are easy-to-handle and cost-effective medical devices that can be used by patients, caregivers, and even untrained personnel to deliver a dose of a particular drug. Autoinjectors are used by patients to manage autoimmune diseases and chronic diseases. They are used for a wide range of indications such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis.

On the basis of type, the autoinjectors market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to account for the largest market share in 2017. This can primarily be attributed to their ease of use and the presence of a built-in glass syringe which makes it more convenient for patients with reduced dexterity or visual impairments.

On the basis of therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, and other therapies (includes cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). The rheumatoid arthritis segment accounted for the largest share of the autoinjectors market in 2017. The large share of this segment is mainly attributed to the high prevalence of rheumatoid arthritis across the globe.

On the basis of end users, the autoinjectors market is segmented into home care settings and hospitals & clinics. The home care settings segment commanded the largest share of the autoinjectors market in 2017. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.

Autoinjectors Market

Autoinjectors applications in various therapeutic indications such as rheumatoid arthritis, diabetes, and anaphylaxis coupled with the growing prevalence of these targeted therapies drive the growth of autoinjectors market

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues. It causes joints to swell and can result in pain, stiffness, and progressive loss of function. Various treatment options are available for RA in the market, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid medicines or injections, conventional disease-modifying anti-rheumatic drugs (cDMARDs), and biological DMARDs (bDMARDs).
Autoinjectors are the most convenient and effective mode of drug delivery option available for this therapeutic indication.

Diabetes

Diabetes mellitus, commonly known as diabetes, is a disease which arises from the insufficient production of insulin or the inability of the body to utilize insulin. The lack of insulin production or the inability of the body to utilize secreted insulin leads to the rise in blood glucose levels. Thus, in order to maintain healthy blood glucose levels, diabetes patients need a daily intake of insulin or Glucagon-like peptide-1 (GLP-1). GLP-1 therapy is delivered through pen devices as well as autoinjector devices. Currently, there are only two autoinjectors available for GLP-1 analogue, namely, Trulicity (dulaglutide) by Eli Lilly and Bydureon BCise (exenatide) by AstraZeneca.

Anaphylaxis

Anaphylaxis is a serious allergic or hypersensitivity reaction that can be life-threatening or fatal. It is characterized by rapidly developing, life-threatening problems involving the airway (pharyngeal or laryngeal edema) and/or breathing (bronchospasm with tachypnoea). Epinephrine autoinjectors are the most preferred mode of drug delivery and treatment option available for this therapy.

Critical questions the report answers:

  • Which of the therapeutic application market will dominate in future?
  • Which regions will provide the high growth opportunities?

Preference for alternative drug delivery modes such as oral diabetic agents, oral insulin, and epinephrine nasal sprays is a major factor restraining the growth of the market. Traditional injectables are invasive and painful modes of drug delivery owing to which patients and care providers are increasingly focusing on alternative routes of drug delivery, such as oral, topical, and nasal routes. Among the various routes of drug delivery, the oral route is the most preferred as it is easy to use, convenient, cost-effective, safe, and acceptable. Moreover, the introduction of needle-free drug delivery devices such as jet injectors also restricts the growth of the autoinjectors market.

Key players in market include Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US). These players adopted growth strategies such as product launches, product approvals, agreements and expansions to maintain and enhance their position in the market. Other prominent players in the market include Ypsomed (Switzerland), Merck (Germany), AstraZeneca (UK), J&J (US), Bayer (Germany), Becton, Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), and Haselmeier (Switzerland).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 14)
    1.1 Objectives of Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Years Considered for the Study
           1.3.2 Markets Covered
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 17)
    2.1 Research Methodology Steps
    2.2 Secondary and Primary Research Methodology
           2.2.1 Secondary Research
           2.2.2 Primary Research
                    2.2.2.1 Key Data From Primary Sources
                    2.2.2.2 Key Industry Insights
    2.3 Market Size Estimation Methodology
    2.4 Market Data Validation and Triangulation
    2.5 Assumptions for the Study

3 Executive Summary (Page No. - 27)

4 Premium Insights (Page No. - 31)
    4.1 Autoinjectors Market Overview
    4.2 Autoinjectors Market, By Type, 2018 vs 2023
    4.3 Geographic Analysis: Autoinjectors Market, By Therapy
    4.4 Autoinjectors Market, By End User, 2018 vs 2023
    4.5 Geographic Snapshot: Autoinjectors Market

5 Market Overview (Page No. - 35)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Growing Prevalence of Targeted Therapies
                    5.2.1.2 Rising Incidence of Anaphylaxis
                    5.2.1.3 Increasing Number of Regulatory Approvals
                    5.2.1.4 Availability of Generic Versions of Autoinjectors
                    5.2.1.5 Favorable Reimbursements and Government Support
                    5.2.1.6 Technological Advancements and Design Development
           5.2.2 Restraints
                    5.2.2.1 Preference for Alternative Drug Delivery Modes
                               5.2.2.1.1 Oral Diabetic Agents and Oral Insulin
                               5.2.2.1.2 Epinephrine Nasal Sprays
           5.2.3 Opportunities
                    5.2.3.1 Patent Expiry of Biologics to Drive the Demand for Biosimilars
           5.2.4 Challenges
                    5.2.4.1 Development of Autoinjectors for Multiple Drug Viscosities
                    5.2.4.2 Lack of Proper Training for Using Autoinjectors

6 Autoinjectors Market, By Therapy (Page No. - 42)
    6.1 Introduction
    6.2 Rheumatoid Arthritis
    6.3 Multiple Sclerosis
    6.4 Diabetes
    6.5 Anaphylaxis
    6.6 Other Therapies

7 Autoinjectors Market, By Type (Page No. - 50)
    7.1 Introduction
    7.2 Disposable Autoinjectors
    7.3 Reusable Autoinjectors

8 Autoinjectors Market, By End User (Page No. - 55)
    8.1 Introduction
    8.2 Home Care Settings
    8.3 Hospitals & Clinics

9 Autoinjectors Market, By Region (Page No. - 60)
    9.1 Introduction
    9.2 North America
           9.2.1 US
           9.2.2 Canada
    9.3 Europe
           9.3.1 Germany
           9.3.2 UK
           9.3.3 France
           9.3.4 Rest of Europe
    9.4 Asia Pacific
           9.4.1 Japan
           9.4.2 China
           9.4.3 India
           9.4.4 RoAPAC
    9.5 Rest of the World

10 Competitive Landscape (Page No. - 94)
     10.1 Overview
     10.2 Market Share Analysis
     10.3 Market Ranking of OEM Companies
     10.4 Market Share Analysis, By Therapeutic Area
             10.4.1 Rheumatoid Arthritis
             10.4.2 Multiple Sclerosis
             10.4.3 Diabetes
             10.4.4 Anaphylaxis
     10.5 Competitive Scenario
             10.5.1 Product Launches and Approvals
             10.5.2 Expansions
             10.5.3 Agreements, Collaborations, and Partnerships

11 Company Profiles (Page No. - 101)
(Business Overview, Products Offered, Recent Developments, MnM View)*
     11.1 Abbvie
     11.2 Mylan
     11.3 ELI Lilly
     11.4 Ypsomed
     11.5 Amgen
     11.6 Becton, Dickinson and Company
     11.7 Owen Mumford
     11.8 Consort Medical
     11.9 Haselmeier
     11.10 Shl Group (Scandinavian Health Limited)
     11.11 Johnson & Johnson (J&J)
     11.12 Teva
     11.13 Antares Pharma

*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. - 125)
     12.1 Discussion Guide
     12.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
     12.3 Available Customizations
     12.4 Related Reports
     12.5 Author Details


List of Tables (66 Tables)

Table 1 Recent Approvals of Autoinjector Devices Across the Globe
Table 2 Patent Expiry of Key Biologics
Table 3 Autoinjectors Market, By Therapy, 2016–2023 (USD Billion)
Table 4 Autoinjectors Market for Rheumatoid Arthritis, By Country, 2016–2023 (USD Billion)
Table 5 Autoinjectors Market for Multiple Sclerosis, By Country, 2016–2023 (USD Billion)
Table 6 Autoinjectors Market for Diabetes, By Country, 2016–2023 (USD Million)
Table 7 Autoinjectors Market for Anaphylaxis, By Country, 2016–2023 (USD Million)
Table 8 Autoinjectors Market for Other Therapies, By Country, 2016–2023 (USD Million)
Table 9 Comparison of Disposable & Reusable Autoinjectors
Table 10 Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 11 Disposable Autoinjectors Market, By Country, 2016–2023 (USD Billion)
Table 12 Reusable Autoinjectors Market, By Country, 2016–2023 (USD Million)
Table 13 Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 14 Autoinjectors Market for Home Care Settings, By Country, 2016–2023 (USD Billion)
Table 15 Autoinjectors Market for Hospitals & Clinics, By Country, 2016–2023 (USD Million)
Table 16 Autoinjectors Market, By Region, 2016–2023 (USD Billion)
Table 17 North America: Autoinjectors Market, By Country, 2016–2023 (USD Billion)
Table 18 North America: Autoinjectors Market, By Therapy, 2016–2023 (USD Billion)
Table 19 North America: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 20 North America: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 21 Autoinjectors Approved By the Fda, 2015–2018
Table 22 US: Autoinjectors Market, By Therapy, 2016–2023 (USD Billion)
Table 23 US: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 24 US: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 25 Canada: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 26 Canada: Autoinjectors Market, By Type, 2016–2023 (USD Million)
Table 27 Canada: Autoinjectors Market, By End User, 2016–2023 (USD Million)
Table 28 Product Approvals in Europe, 2015–2018
Table 29 Europe: Autoinjectors Market, By Country, 2016–2023 (USD Billion)
Table 30 Europe: Autoinjectors Market, By Therapy, 2016–2023 (USD Billion)
Table 31 Europe: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 32 Europe: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 33 Germany: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 34 Germany: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 35 Germany: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 36 UK: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 37 UK: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 38 UK: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 39 France: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 40 France: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 41 France: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 42 RoE: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 43 RoE: Autoinjectors Market, By Type, 2016–2023 (USD Million)
Table 44 RoE: Autoinjectors Market, By End User, 2016–2023 (USD Million)
Table 45 Asia Pacific: Autoinjectors Market, By Country, 2016–2023 (USD Billion)
Table 46 Asia Pacific: Autoinjectors Market, By Therapy, 2016–2023 (USD Billion)
Table 47 Asia Pacific: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 48 Asia Pacific: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 49 Japan: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 50 Japan: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 51 Japan: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 52 China: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 53 China: Autoinjectors Market, By Type, 2016–2023 (USD Million)
Table 54 China: Autoinjectors Market, By End User, 2016–2023 (USD Million)
Table 55 India: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 56 India: Autoinjectors Market, By Type, 2016–2023 (USD Million)
Table 57 India: Autoinjectors Market, By End User, 2016–2023 (USD Million)
Table 58 RoAPAC: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 59 RoAPAC: Autoinjectors Market, By Type, 2016–2023 (USD Million)
Table 60 RoAPAC: Autoinjectors Market, By End User, 2016–2023 (USD Million)
Table 61 RoW: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 62 RoW: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 63 RoW: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 64 Product Launches and Approvals
Table 65 Expansions
Table 66 Agreements, Collaborations, and Partnerships


List of Figures (36 Figures)

Figure 1 Autoinjectors Market: Research Methodology Steps
Figure 2 Break Down of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Research Design
Figure 6 Data Triangulation Methodology
Figure 7 Rheumatoid Arthritis Therapy Segment to Dominate the Autoinjectors Market in 2018
Figure 8 Disposable Autoinjectors to Account for the Largest Share of the Autoinjectors Market in 2018
Figure 9 Home Care Settings to Dominate the Autoinjectors Market During the Forecast Period
Figure 10 North America to Witness the Highest Market Growth During the Forecast Period
Figure 11 Growing Prevalence of Targeted Therapies and Increasing Number of Regulatory Approvals are Driving Market Growth
Figure 12 Disposable Autoinjectors to Dominate the Market in 2018
Figure 13 Rheumatoid Arthritis Therapy Segment to Command the Largest Share of the Autoinjectors Market in 2018
Figure 14 Home Care Settings to Account for the Largest Market Share in 2018
Figure 15 North America to Witness the Highest Growth Rate During the Forecast Period
Figure 16 Autoinjectors Market: Drivers, Restraints, Opportunities, & Challenges
Figure 17 Autoinjectors Market, By Therapy, 2018 vs 2023 (USD Billion)
Figure 18 Autoinjectors Market, By Type, 2018 vs 2023 (USD Billion)
Figure 19 Autoinjectors Market, By End User, 2018 vs 2023 (USD Billion)
Figure 20 North America to Command the Largest Market Share in 2018
Figure 21 North America: Autoinjectors Market Snapshot
Figure 22 Europe: Autoinjectors Market Snapshot
Figure 23 Asia Pacific: Autoinjectors Market Snapshot
Figure 24 RoW: Autoinjectors Market Snapshot
Figure 25 Market Ranking of OEM Companies
Figure 26 Strategies Adopted By Market Players (2014–2018)
Figure 27 Abbvie: Company Snapshot (2017)
Figure 28 Mylan: Company Snapshot (2017)
Figure 29 ELI Lilly: Company Snapshot (2017)
Figure 30 Ypsomed: Company Snapshot (2017)
Figure 31 Amgen: Company Snapshot (2017)
Figure 32 BD: Company Snapshot (2017)
Figure 33 Consort Medical: Company Snapshot (2017)
Figure 34 Johnson & Johnson: Company Snapshot (2017)
Figure 35 Teva: Company Snapshot (2017)
Figure 36 Antares Pharma: Company Snapshot (2017)


Request for detailed methodology, assumptions & how numbers were triangulated.

Our USP is "Customised multi client reports"-so feel free to provide us specific interest in much greater detail..!!
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
MD 6494
Published ON
Aug, 2018
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Autoinjectors Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved